Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06649110 | A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) | PHASE1 | RECRUITING | 232 | — | — | Oct 24, 2024 | Dec 31, 2028 | Apr 29, 2026 | 85 | United States, Argentina +16 |
Safety endpoints, including vital signs, ECG, clinical laboratory evaluations and adverse events up to and including the end-of-study visit.
PVR is a hemodynamic variable of pulmonary circulation and is measured by right heart catheterization.
Safety endpoints, including vital signs, ECG, clinical laboratory evaluations, treatment-emergent adverse events and discontinuations due to adverse events.
| Arm | Type | Description |
|---|---|---|
| LTP001 Dose 1 | EXPERIMENTAL | - |
| LTP001 Dose 2 | EXPERIMENTAL | - |
| LTP001 Dose 3 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | matching placebo |
| Name | Type | Description |
|---|---|---|
| LTP | DRUG | LTP001 |
| Placebo | DRUG | Placebo |
Part A Inclusion Criteria: * Healthy males and non-child-bearing potential females Part A Exclusion Criteria: * Clinically significant ECG or cardiac abnormalities, any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, o...